

Regulation of BCR-ABL expression via its 3'untranslated region

Bradley Chereda

A thesis submitted for the degree of
Doctor of Philosophy
to the University of Adelaide

December 2012

School of Medicine
Faculty of Health Sciences
University of Adelaide

Leukaemia Biology Group
Centre for Cancer Biology
IMVS, SA Pathology

Declaration

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution to Bradley Chereda and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue, the Australasian Digital Theses Program (ADTP) and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Bradley Chereda

December 2012

Table of contents

Declaration.....	III
Table of contents.....	V
Abstract.....	XII
Acknowledgements.....	XIII
Abbreviations.....	XV
Chapter 1.....	1
Chronic myeloid leukaemia	1
1.1 Preface.....	2
1.2 Chronic myeloid leukaemia.....	2
1.3 Disease pathogenesis	3
1.3.1 Chronic phase	4
1.3.2 Blast crisis.....	4
1.3.3 Treatment	4
1.4 BCR-ABL	5
1.4.1 BCR-ABL signalling in disease.....	7
1.4.1.1 Proliferation and apoptosis	8
1.4.1.2 Genomic instability.....	9
1.4.2 Expression patterns of BCR-ABL in CML.....	10
1.4.3 BCR-ABL dosage	12
1.4.3.1 Association with blast crisis.....	12
1.4.3.1.1 Dose-dependent downregulation of C/EBP α	12
1.4.3.1.2 Dose-dependent inhibition of DNA repair	13
1.4.3.2 BCR-ABL levels and imatinib resistance.....	13
1.4.3.3 BCR-ABL expression and TKI-sensitivity in leukaemic stem cells.....	14
1.4.4 Control of BCR-ABL expression	15
1.4.4.1 The BCR Promoter	16
1.4.4.2 DNA/histone modifications relative to BCR-ABL.....	17
1.4.4.3 The BCR-ABL 3'UTR.....	18
1.4.4.4 BCR-ABL is abnormal	18
1.4.4.5 The key regulators of BCR-ABL expression are known, now what?	19
1.5 Specific aims	21

Chapter 2	22
Characterisation of the <i>ABL1</i> 3'UTR	22
2.1 <i>Introduction</i>	23
2.1.1 The 3'UTR	23
2.1.1.1 The PAS	24
2.1.1.2 MicroRNAs	24
2.1.1.3 RNA-binding proteins.....	25
2.1.1.4 3'UTR avoidance	25
2.1.2 The <i>BCR-ABL</i> 3'UTR.....	28
2.1.2.1 What is known about the <i>BCR-ABL</i> 3'UTR	28
2.1.2.2 3'UTR shortening of <i>ABL1</i>	31
2.1.2.3 Investigating the <i>BCR-ABL</i> 3'UTR	31
2.2 <i>Methods</i>	33
2.2.1 Renilla reporter constructs.....	33
2.2.1.1 <i>ABL1</i> 3'UTR reporters (PCR-based)	34
2.2.1.1.1 PCR	34
2.2.1.1.2 Restriction digest cloning.....	36
2.2.1.2 <i>ABL1</i> 3'UTR reporters (restriction site-based)	36
2.2.1.3 <i>ABL1</i> 3'UTR reporters (restriction site insertion-based)	36
2.2.1.4 Blunt-end cloning: phRL- <i>ABL1</i> 3'UTR (1-840)	39
2.2.1.5 Duplex insertion: phRL-FL- <i>ABL1</i> (PAS) and phRL-FL- <i>ABL1</i> (SAP)	39
2.2.1.5.1 Oligo-duplex annealing	40
2.2.1.5.2 Restriction digest cloning.....	40
2.2.1.6 phRL- <i>ABL1</i> (1116-1257) and phRL- <i>ABL1</i> (1116-1257) Δ TTP	41
2.2.1.7 Transformation	42
2.2.1.8 DNA plasmid prep	42
2.2.1.9 Plasmid amplification.....	42
2.2.2 Firefly reporter constructs.....	42
2.2.3 PCR (qualitative)	43
2.2.4 PCR (mutagenesis).....	43
2.2.5 PCR (quantitative).....	44
2.2.6 Protein expression analysis	44
2.2.6.1 Protein lysates.....	45
2.2.6.2 SDS PAGE and Western transfer	45
2.2.6.3 Western blotting.....	45
2.2.7 Cell culture.....	46

2.2.7.1	Imatinib treatment	46
2.2.8	Transient transfection	46
2.2.8.1	FuGene 6	47
2.2.8.2	X-tremeGENE and X-tremeGENE HP	47
2.2.8.3	Lipofectamine	48
2.2.8.4	MicroRNA induction	49
2.2.9	Bioinformatics	49
2.3	Results	49
2.3.1	<i>BCR-ABL</i> and <i>ABL1</i> have similar and shorter half-lives than <i>BCR</i>	49
2.3.2	Defining the <i>ABL1</i> 3'UTR	50
2.3.2.1	3' RACE identifies a number of putative <i>ABL1</i> 3'UTR products	50
2.3.2.2	The shortened 3'UTR is found in less than 2% of all <i>ABL1</i> 3'UTR containing transcripts	53
2.3.2.3	No evidence of a distal poly-adenylation site for <i>ABL1</i>	53
2.3.3	Optimising transient transfections in haemopoietic cell lines	56
2.3.3.1	FuGene 6	57
2.3.3.2	X-tremeGENE-HP	59
2.3.4	The full-length <i>ABL1</i> 3'UTR is repressive	60
2.3.4.1	Imatinib-exposure alters <i>BCR-ABL</i> expression	61
2.3.5	<i>ABL1</i> 3'UTR-mediated repression occurs at the RNA level	64
2.3.6	Discrete regions of the <i>ABL1</i> 3'UTR affect reporter expression	65
2.3.6.1	5' truncations of the <i>ABL1</i> 3'UTR	65
2.3.6.2	3' sequential additions of the <i>ABL1</i> 3'UTR	67
2.3.7	The region spanning nt 1116-1287 of the <i>ABL1</i> 3'UTR is repressive	69
2.3.7.1	TTP binding site	70
2.3.7.2	MicroRNA-125	71
2.3.8	The region spanning nt 821-940 of the <i>ABL1</i> 3'UTR is repressive	72
2.3.8.1	The 96 and 142 nt repressors have an additive effect on reporter expression	72
2.3.9	Merging the deletion mapping data	73
2.3.10	3'UTR avoidance	74
2.3.10.1	No evidence for <i>ABL1</i> 3'UTR-containing pseudogenes	74
2.3.10.2	The <i>ABL1</i> 3'UTR is unlikely to be independently transcribed from <i>ABL1</i>	75
2.3.11	<i>In silico</i> screen for <i>ABL1</i> 3'UTR regulatory elements	76
2.3.11.1	Predicted microRNA binding sites in the <i>ABL1</i> 3'UTR	77
2.3.11.2	RNA-binding proteins	77
2.3.11.2.1	Predicted RNA-binding protein binding sites	77
2.3.11.2.2	RNA-immunoprecipitation data	79

2.4 Discussion.....	84
Chapter 3	93
MicroRNA regulation of BCR-ABL.....	93
3.1 Introduction.....	94
3.1.1 MicroRNA	94
3.1.2 MicroRNA biogenesis	95
3.1.2.1 Transcription and export.....	95
3.1.2.2 Formation of the mature microRNA	97
3.1.2.3 MicroRNA modus operandi.....	97
3.1.2.4 MicroRNA seed sequence	97
3.1.2.5 Nomenclature	98
3.1.2.6 MicroRNA target prediction.....	99
3.1.2.7 MicroRNAs in haemopoiesis	99
3.1.2.8 Leukaemia.....	100
3.1.2.8.1 MicroRNAs and CML	101
3.2 Methods.....	102
3.2.1 Bioinformatics prediction of microRNA interactions with <i>ABL1</i>	102
3.2.2 Cell culture.....	102
3.2.3 Luciferase reporter system for screening putative microRNA interactions with the <i>BCR-ABL</i>	
3'UTR	102
3.2.3.1 Construction of luciferase reporters.....	103
3.2.3.1.1 PCR	103
3.2.3.1.2 Restriction digest.....	103
3.2.3.1.3 Cloning procedure.....	103
3.2.3.1.4 Mutagenesis of predicted microRNA binding sites	104
3.2.3.2 Transient transfection (Lipofectamine)	104
3.2.3.3 Transient transfection of K-562 cells with microRNA mimics	105
3.2.4 MicroRNA over-expression in CML cell lines	105
3.2.4.1 MicroRNA expression constructs	105
3.2.4.2 Cell line over-expression.....	106
3.2.4.2.1 Over-expression of miR-196b.....	106
3.2.5 MicroRNA expression analysis.....	107
3.2.5.1 cDNA synthesis.....	107
3.2.5.2 Small RNA quantification	108
3.2.6 Protein expression analysis	108

3.2.7	Proliferation assays	109
3.3	<i>Results</i>	109
3.3.1	Bioinformatics	109
3.3.2	<i>BCR-ABL</i> 3'UTR reporter response to microRNA induction	111
3.3.2.1	Transfection optimisation: Pre-miR.....	111
3.3.2.2	Transfection optimisation: time	112
3.3.2.3	Apart from miR-30a, the miR-30 family and miR-203 do not specifically interact with <i>BCR-ABL</i> 3'UTR luciferase reporters.....	113
3.3.2.4	The miR-29 and 196 families specifically interact with <i>BCR-ABL</i> 3'UTR luciferase reporters	114
3.3.3	MicroRNA over-expression in CML cell lines.....	115
3.3.3.1	Over-expression of miR-29	115
3.3.3.2	Over-expression of miR-30.....	116
3.3.3.3	Over-expression of miR-203.....	117
3.3.3.4	Over-expression of miR-196b.....	119
3.3.3.5	AGO2 RIP-SEQ.....	121
3.3.3.5.1	Transient transfection of miR-141 in K-562 cells.....	122
3.4	<i>Discussion</i>	125
Chapter 4.....		130
Developing an assay to identify <i>ABL1</i> 3'UTR binding proteins		130
4.1	<i>Introduction</i>	131
4.1.1	RNA-binding proteins.....	131
4.1.2	RNA-binding proteins in development and disease.....	133
4.1.2.1	RNA-binding proteins in chronic myeloid leukaemia	133
4.1.2.2	Modulation of <i>BCR-ABL</i> stability by RNA-binding proteins	134
4.1.3	Methods for RNA-binding protein isolation.....	135
4.1.3.1	RNA aptamers.....	137
4.1.3.1.1	Streptavidin aptamers	137
4.1.3.1.2	StreptoTag	137
4.1.3.1.3	MS2 coat protein aptamer.....	137
4.1.3.2	Biotinylation	138
4.1.3.3	Mass spectrometry-based identification of proteins	139
4.2	<i>Methods</i>	141
4.2.1	Developing an assay to capture RNA-binding proteins that interact with the <i>BCR-ABL</i> 3'UTR. ..	141

Table of Contents

4.2.2	Cell culture.....	141
4.2.3	S1 RNA-aptamer	142
4.2.3.1	S1-aptamer constructs.....	142
4.2.3.1.1	Cloning the S1-tag into the pUC19 intermediate	142
4.2.3.1.1.1	Oligonucleotide duplex annealing	142
4.2.3.1.1.2	<i>EcoRI</i> restriction digest	142
4.2.3.1.1.3	DNA purification, ligation and transformation	142
4.2.3.1.1.4	DNA plasmid prep	143
4.2.3.1.2	Cloning the S1-tag into the pBluescript II SK+ intermediate	143
4.2.3.1.3	Cloning the S1-tag into the full length ABL1 3'UTR.....	144
4.2.3.2	Transient transfection: luciferase assay.....	144
4.2.3.3	S1-aptamer enrichment assay 1	144
4.2.3.3.1	Transfection of HeLa cells with phRL-ABL3'UTR-S1	144
4.2.3.3.2	Streptavidin agarose S1-tagged RNA enrichment.....	145
4.2.3.4	S1-aptamer enrichment assay 2	145
4.2.3.4.1	Transfection of HeLa cells with phRL-ABL3'UTR-S1	145
4.2.3.4.2	Streptavidin agarose S1-tagged RNA enrichment.....	146
4.2.3.5	RNA isolation.....	146
4.2.3.5.1	cDNA synthesis.....	146
4.2.3.5.2	Quantitative PCR	147
4.2.3.5.3	G6PD qualitative PCR	147
4.2.3.6	Streptavidin agarose binding assay.....	147
4.2.3.6.1	In vitro transcription	147
4.2.3.6.2	Binding assay.....	148
4.2.3.6.3	Non-denaturing polyacrylamide-gel electrophoresis.....	148
4.2.4	Biotinylation of <i>BCR-ABL</i> 3'UTR RNA	148
4.2.4.1	T7 promoter-driven <i>BCR-ABL</i> 3'UTR vectors.....	148
4.2.4.2	<i>In vitro</i> transcription	149
4.2.4.3	Streptavidin agarose binding assay.....	149
4.2.4.4	RNA-binding protein pullout assay	150
4.2.4.4.1	TCA precipitation.....	151
4.2.4.4.2	Protein gel electrophoresis	152
4.2.4.4.3	Silver staining	152
4.2.4.4.4	Gel image capture	152
4.2.5	Next generation S1 aptamer	153
4.2.5.1	T7 promoter-driven tethered-S1-aptamer <i>BCR-ABL</i> 3'UTR vectors.....	153
4.2.5.2	<i>In vitro</i> transcription	153

4.2.5.3	Streptavidin agarose binding assay	154
4.2.5.4	RNA-binding protein pullout assay (assay VIII).....	154
4.2.5.4.1	Protein gel electrophoresis.....	154
4.2.6	Mass spectrometry	154
4.3	<i>Results</i>	154
4.3.1	The S1-RNA aptamer.....	155
4.3.1.1	Intra <i>ABL1</i> 3'UTR insertion of the S1-tag does not affect luciferase expression	155
4.3.1.2	Streptavidin agarose did not enrich S1-tagged RNA	155
4.3.2	Biotinylation of the <i>BCR-ABL</i> 3'UTR	158
4.3.2.1	Streptavidin agarose enriched biotinylated RNA	159
4.3.2.2	Optimisation of RNA-binding protein capture using biotin-tagged <i>ABL1</i> 3'UTR RNA	160
4.3.3	Next-gen tRNA-tethered-S1-tag.....	165
4.3.3.1	Streptavidin agarose enriched tRNA-tethered-S1-tagged RNA.....	165
4.3.3.2	RNA-binding protein isolation	166
4.3.3.3	Mass spectrometry analysis	168
4.4	<i>Discussion</i>	169
Chapter 5	174
Conclusions	174
5.1	<i>Overall conclusions</i>	175
5.2	<i>Future directions: Q & A</i>	178
Appendix A: Common experimental protocols	184
Appendix B: Reagents and solutions	193
Appendix C: Supplementary data	199
Appendix D: Permissions	210
References	217

Abstract

In patients with chronic myeloid leukaemia (CML), a translocation between chromosomes 9 and 22 fuses the *BCR* gene with the *ABL1* gene, and gives rise to the *BCR-ABL* gene. Expression of the BCR-ABL protein initiates and drives CML. The level of BCR-ABL expression is associated with disease progression and response to therapy, yet control of BCR-ABL expression is poorly understood. This study has added to this limited knowledge-base by investigating the role that the *BCR-ABL* 3'untranslated region (3'UTR) plays in controlling BCR-ABL expression. Due to the nature of the translocation, the *BCR-ABL* 3'UTR is contributed by the *ABL1* gene. We found that *ABL1* and *BCR-ABL* have similar, but shorter half-lives than *BCR*. This suggests that the *ABL1* moiety influences the stability of the *BCR-ABL* transcript. Addition of the *ABL1* 3'UTR to a *Renilla* reporter gene strongly repressed reporter expression. Furthermore, insertion of a premature poly-adenylation site in the 3'UTR resulted in a rescue of reporter expression, demonstrating that the 3'UTR is required in the transcript for full activity, and thus is indicative of post-transcriptional control. Generation of *ABL1* reporters containing various regions of the 3'UTR revealed that discrete regions of the 3'UTR could strongly influence gene expression. Following these results, we attempted to identify factors involved in the regulation of BCR-ABL expression. We focused on microRNAs-29, 30, 125, 141, 196 and 203, predicted by bioinformatics to interact with the 3'UTR. Although some of these microRNAs interacted with *ABL1* reporters, they did not modulate endogenous BCR-ABL expression. In parallel, we developed an assay that was aimed at identifying RNA-binding proteins that bind to the *ABL1* 3'UTR. Finally, using publically-available datasets, we found data suggesting that RNA-binding proteins; TTP, hnRNP-C, ELAVL-1, TIA-1 and TIAL-1 interact with functional regulatory regions of the *ABL1* 3'UTR.

Taken together, we have shown that the *BCR-ABL* 3'UTR sequence is repressive, and contains discrete regions that can influence gene expression. The 3'UTR is located within a region of the *BCR-ABL* transcript that is responsible for controlling *BCR-ABL* mRNA stability. Although many attempts were made to discover functional *ABL1* 3'UTR binding factors, their identities remain unknown. Further research is required to identify the binding factors involved. We envisage that a comprehensive understanding of how BCR-ABL is controlled will contribute to a better understanding of the biology of CML, and pave the way for innovative forms of targeted therapy.

Acknowledgements

I would first and foremost like to thank my supervisors Prof. Junia Vaz de Melo and Dr Duncan Hewett for taking me on as a PhD student, for your excellent guidance, time, effort and patience committed to ensure I have a thesis to hand in. It was a privilege to be in the trenches (or Bay-One) with you Duncan, I learned all the old-school tricks and tips needed to get by in the lab, and our camaraderie helped me get through my PhD. I am also grateful to Junia for giving me a free-ride to do whatever experiments I thought would add to the project (thought were cool), as well as being our CML-guru. I learned a lot in all these respects. I *leave you* both with the ability to fill in forms.

Secondly, I would like to thank past and present members of the Leukaemia Biology Group. The Lads™ (Jun and Stanley) cheers for your friendship, many laughs and fun were had. Mark, thanks for the banter throughout my second year (I am nearly over ‘clone-gate’). Deborà, thanks for your patient ear, as well as your stories of Brazil. Thanks to Ljiljana, as both a member of team-3’UTR and for your wise words. Veera, thanks for keeping the results ticking over during my write-up. I thank all of you and Brett, Vicksta™, Angela, Linda, Tess, Annabel, Gink and Fong for your invaluable support on and off the bench, and making it that much easier to complete my PhD.

I was also fortunate enough to be able to steal plasmids/bounce ideas off: Greg Goodall, Emily Paterson and Cameron Bracken (microRNAs), and Ian Macara, Hidekazu Lioka, Jason Weber, Mary Olanich, Kirk Jenson and Ashwin Unnikrishnan (RNA-binding proteins). Thanks also to the other laboratories within the IMVS that provided equipment/support throughout my research. I’m also appreciative of the Flow-Lab staff for your help with everything relating to FACS in this project, the Proteomics Facility for mass-spectrometry work, and Tony Cambareri for keeping the institute together (even still, I managed to convince Junia that our lab burnt down!).

I would not have been able to complete this PhD without the help of various funding bodies. I was the recipient of a three-year ‘Australian Postgraduate Award’ from the Australian government. I was able to attend the 17th Congress of the European Hematology Association, in Amsterdam, due to a “coalition” of travel grants from the Adelaide University’s ‘Postgraduate Travel Fund’, a grant from the SPMSFF (SA Pathology), and a travel grant from the conference itself. I also received a travel grant from the European Molecular Biology Organisation to attend the “Complex life of mRNA” symposium in Heidelberg in October 2012. I also thank Junia for keeping me on after my scholarship ended so I could still ~~go for a pint~~ eat during the write up of my thesis.

Acknowledgements

I am also grateful for the hospitality provided by the members of the various laboratories I visited in Europe. Dankeschön to Alex, Caroline, Leon and Stan; Florian, Roberto and fellow Aussie Keriyn! Grazie tanto to Emanuele, Monica and Simona! And, dekuji pekne to Tereza and Marketa for the wonderful time I had in Prague.

Finally, I express my appreciation to my family and friends that have provided considerable support since embarking on my PhD and throughout my studies.

Abbreviations

2D	2-dimensional
7mG	7'-methyl guanine cap
AANAT	Aralkylamine N-acetyltransferase
ABL1	Abelson gene
AGO	Argonaute
ALL	Acute lymphoblastic leukaemia
AML	Acute myeloid leukaemia
ANKFN1	Ankyrin-repeat and fibronectin type III domain containing 1
AP	Alkaline phosphatase
ASF	see SFRS1
ATP	Adenosine tri-phosphate
AU-RE	AU-rich element
Aza	5-Azacytidine
BC	Blast crisis
BCL2	B-cell lymphoma 2
BCR	Breakpoint cluster region
<i>bone fide</i>	<i>in good faith, genuine</i>
BSA	Bovine serum albumin
C/EBP α	CCAAT/enhancer-binding protein alpha
CAGE	Capped analysis of gene expression
CDC42	Cell division control protein 42 homolog
CDCA	Chenodeoxycholic acid
CDK4	Cyclin-dependent kinase 4
cDNA	complementary DNA
CHOP	CCAAT/enhancer-binding protein homologous protein
CID	Collision-induced dissociation
CIP	Alkaline phosphatase
<i>cis</i>	on the same side
CLL	Chronic lymphocytic leukaemia
CML	Chronic myeloid leukaemia
CMP	Common myeloid progenitor
CNL	Chronic neutrophilic leukaemia
COL1a1	Collagen type I alpha1
CP	Chronic phase
CRB3	Crumbs homolog 3
DEPC	Diethylpyrocarbonate
DGCR8	DiGeorge syndrome critical region gene 8
DNA	Deoxy-ribose nucleic acid
DNA-PKcs	DNA-dependent protein kinase, catalytic subunit

Abbreviations

DNMT3A	DNA (cytosine-5-)-methyltransferase 3 alpha
DSB	Double-stranded breaks
ELAVL	(Embryonic lethal, abnormal vision, Drosophila)-like
EST	Expressed sequence tag
<i>et al</i>	<i>and others</i>
etc	ecetera
<i>ex vivo</i>	<i>out of the living</i>
FACS	Fluorescence-activated cell sorting, Flow cytometry
FOXO3	Forkhead box O3
FUS	Fused in sarcoma
GFP	Green fluorescent protein
GMP	Granulocyte-macrophage progenitor
GRP58	see PDIA3
GUS-B	Glucuronidase beta
HNF4 α	Hepatocyte nuclear factor 4 alpha
hnRNP	heterogeneous nuclear ribonucleoprotein
HOX-B7	Homeobox B7
HPLC	High-performance liquid chromatography
HSC	Haemopoietic stem cell
HuR	ELAVL-1
IFN γ	Interferon gamma
IGF2BP	Insulin-like growth factor 2 binding protein
IL	Interleukin
IMP	see IGF2BP
IMPDH2	Inosine-5'-monophosphate dehydrogenase 2
<i>in silico</i>	<i>performed on computer</i>
<i>in vitro</i>	<i>in glass</i>
<i>in vivo</i>	<i>within the living</i>
JAK	Janus kinase
kb	kilobases
kDa	kilo dalton
KH	K-homology
KRAS	Kirsten rat sarcoma viral oncogene homolog
LB	Luria broth
LC-eSI-IT	Liquid chromatography-electrospray ionisation ion-trap mass spectrometry
LDLR	Low density lipoprotein receptor
LT-HSC	Long-term HSC
LTR	Long terminal repeat
m/z	mass/charge
max	maximum
MCL	Mantle-cell lymphoma
Me	Methylation

Meg ^K	Megakaryocyte
MEP	Megakaryocyte-erythroid progenitor
MMR	Major molecular response
<i>modus operandi</i>	<i>mode of operation</i>
MR	Molecular response
mRNA	messenger RNA
MS-MS	Tandem mass spectrometry
next-gen	next-generation
NPM1	Nucleophosmin
nt	nucleotide
NUMB	Numb homolog
Oct4	octamer-binding transcription factor 4
PACT	protein activator of PKR
PAS	Poly adenylation signal
PBA	4-Phenylbutyric acid
PBMNC	Perhiperal blood mononuclear cell
PCR	Polymerase chain reaction
PDIA3	Protein disulphide-isomerase A3
Ph	Philadelphia
PhD	Doctor of philosophy
PI3K	Phosphoinositide 3-kinase
PKC β II	Protein kinase C β II
PMSF	Phenylmethylsulfonyl fluoride
poly-A	poly-adenosine
PP2A	Protein phosphatase 2A
Pre-miRNA	Precursor-microRNA
Pri-miRNA	Primary-microRNA
PTEN	Phosphatase and tensin homolog
PTENP1	PTEN pseudogene 1
qRT-PCR	Quantitative real-time PCR
RACE	Rapid amplification of cDNA ends
RB	Retinoblastoma (gene)
RBC	Red blood cell
RBD	RNA-binding domain
RIP-SEQ	Immunoprecipitation of proteins coupled with next-gen sequencing
RISC	RNA-induced silencing complex
RNA	Ribonucleic acid
ROS	Reactive oxygen species
RRM	RNA-recognition motif
SD	Standard deviation
SEM	Standard error of the mean
SFRS1	Splicing factor, arginine/serine-rich 1

Abbreviations

SH1	Src homology domain 1
siRNA	silencing RNA
SILAC	Stable isotope labelling with amino acids in cell culture
SNP	Single nucleotide polymorphisms
ssRNA	single-stranded RNA
STAT5	Signal transducer and activator of transcription 5
ST-HSC	Short-term HSC
TIA-1	T-cell-restricted intracellular antigen-1
TIAL-1	TIA-like-1
TKI	Tyrosine kinase inhibitor
TLS	Translocated in liposarcoma
TNF	Tumour necrosis factor
<i>trans</i>	opposite side
TRBP	HIV transactivating response RNA binding protein
TTP	Tristetraprolin
UTR	Untranslated region
UV	Ultraviolet
<i>vice versa</i>	<i>the other way around</i>
<i>vs.</i>	<i>versus</i>
ZFP36	see TTP